Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-01-19

AUTHORS

R. De Vecchis, C. Ariano, G. Di Biase, M. Noutsias

ABSTRACT

BackgroundThe combination drug sacubitril/valsartan was reported to be superior to enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) hospitalizations in patients with cardiac insufficiency and reduced left ventricular ejection fraction (HFREF) with NYHA class II–IV.MethodsOur retrospective cohort study aimed to assess the effects of sacubitril/valsartan in addition to a beta-blocker and mineral receptor antagonist (MRA) in a group of HFREF patients with NYHA class II–III HF vs. conventional therapy (ACE inhibitor or angiotensin II receptor blocker added to a beta-blocker plus an MRA) administered to a control group of HFREF patients with comparable clinical features. In both groups, treatment was supplemented by a loop diuretic, usually furosemide, at variable doses. The primary outcomes were all-cause death and HF hospitalizations. Safety outcomes were symptomatic hypotension, angioedema, hyperkalemia, and worsening renal function.ResultsMortality at 6 months was 6.8% in patients taking sacubitril/valsartan vs. 34% in those on conventional therapy (odds ratio [OR] = 0.14; 95% CI: 0.04–0.49). Moreover, there was a 4.5% rate of HF hospitalizations in the sacubitril/valsartan group vs. 59% in the control group (OR = 0.03; 95% CI: 0.01–0.14). Safety outcomes were comparable in the two groups, although hypotension (systolic blood pressure < 100 mm Hg) was found in 15.9% of patients in the sacubitril/valsartan group vs. 5.7% in the control group (OR = 3.14; 95% CI: 0.94–10.55).ConclusionSacubitril/valsartan offered strong protection against all-cause death and HF hospitalizations at 6 months without any significant side effects. To validate this efficacious molecule, further postmarketing observational studies, focusing mainly on hypotension and angioedema are warranted. More... »

PAGES

425-432

References to SciGraph publications

  • 2013-04-17. Natriuretic peptide-guided therapy in HERZ
  • 2017-09-22. Acute heart failure in HERZ
  • 2017-03-09. Potential Expanded Indications for Neprilysin Inhibitors in CURRENT HEART FAILURE REPORTS
  • 2016-12-22. Sacubitril/Valsartan (LCZ696) in Heart Failure in HEART FAILURE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00059-017-4671-1

    DOI

    http://dx.doi.org/10.1007/s00059-017-4671-1

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1100478773

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/29350254


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aminobutyrates", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antihypertensive Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Combinations", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Heart Failure", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neprilysin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Retrospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Stroke Volume", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tetrazoles", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Valsartan", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Preventive Cardiology and Rehabilitation Unit, DSB 29 \u201cS.\u00a0Gennaro dei Poveri Hospital\u201d, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Preventive Cardiology and Rehabilitation Unit, DSB 29 \u201cS.\u00a0Gennaro dei Poveri Hospital\u201d, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "De Vecchis", 
            "givenName": "R.", 
            "id": "sg:person.0704361014.79", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704361014.79"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Geriatrics, Casa di Cura \u201cSollievo della Sofferenza\u201d, viale Cappuccini\u00a02, 71013, San Giovanni Rotondo, Italy", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Preventive Cardiology and Rehabilitation Unit, DSB 29 \u201cS.\u00a0Gennaro dei Poveri Hospital\u201d, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy", 
                "Division of Geriatrics, Casa di Cura \u201cSollievo della Sofferenza\u201d, viale Cappuccini\u00a02, 71013, San Giovanni Rotondo, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ariano", 
            "givenName": "C.", 
            "id": "sg:person.0660263343.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660263343.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Geriatrics, Clinic \u201cS. Maria del Pozzo\u201d, via Pomigliano\u00a040, 80049, Somma Vesuviana, Italy", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Division of Geriatrics, Clinic \u201cS. Maria del Pozzo\u201d, via Pomigliano\u00a040, 80049, Somma Vesuviana, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Di Biase", 
            "givenName": "G.", 
            "id": "sg:person.01066703417.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066703417.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst Grube-Stra\u00dfe\u00a040, 06120, Halle, Germany", 
              "id": "http://www.grid.ac/institutes/grid.9018.0", 
              "name": [
                "Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst Grube-Stra\u00dfe\u00a040, 06120, Halle, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Noutsias", 
            "givenName": "M.", 
            "id": "sg:person.01077606445.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077606445.25"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s11897-017-0327-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1084033357", 
              "https://doi.org/10.1007/s11897-017-0327-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00059-017-4626-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091896405", 
              "https://doi.org/10.1007/s00059-017-4626-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00059-013-3772-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047353802", 
              "https://doi.org/10.1007/s00059-013-3772-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/164_2016_77", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000389269", 
              "https://doi.org/10.1007/164_2016_77"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2018-01-19", 
        "datePublishedReg": "2018-01-19", 
        "description": "BackgroundThe combination drug sacubitril/valsartan was reported to be superior to enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) hospitalizations in patients with cardiac insufficiency and reduced left ventricular ejection fraction (HFREF) with NYHA class\u00a0II\u2013IV.MethodsOur retrospective cohort study aimed to assess the effects of sacubitril/valsartan in addition to a\u00a0beta-blocker and mineral receptor antagonist (MRA) in a\u00a0group of HFREF patients with NYHA class\u00a0II\u2013III HF vs. conventional therapy (ACE inhibitor or angiotensin\u00a0II receptor blocker added to a beta-blocker plus an\u00a0MRA) administered to a\u00a0control group of HFREF patients with comparable clinical features. In both groups, treatment was supplemented by a\u00a0loop diuretic, usually furosemide, at variable doses. The primary outcomes were all-cause death and HF hospitalizations. Safety outcomes were symptomatic hypotension, angioedema, hyperkalemia, and worsening renal function.ResultsMortality at 6\u00a0months was 6.8% in patients taking sacubitril/valsartan vs. 34% in those on conventional therapy (odds ratio [OR]\u00a0= 0.14; 95% CI: 0.04\u20130.49). Moreover, there was a 4.5% rate of HF hospitalizations in the sacubitril/valsartan group vs. 59% in the control group (OR\u00a0= 0.03; 95% CI: 0.01\u20130.14). Safety outcomes were comparable in the two groups, although hypotension (systolic blood pressure <\u202f100\u2009mm\u00a0Hg) was found in 15.9% of patients in the sacubitril/valsartan group vs. 5.7% in the control group (OR\u00a0= 3.14; 95% CI: 0.94\u201310.55).ConclusionSacubitril/valsartan offered strong protection against all-cause death and HF hospitalizations at 6\u00a0months without any significant side effects. To validate this efficacious molecule, further postmarketing observational studies, focusing mainly on hypotension and angioedema are warranted.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00059-017-4671-1", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1087175", 
            "issn": [
              "0340-9937", 
              "1615-6692"
            ], 
            "name": "Herz", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "44"
          }
        ], 
        "keywords": [
          "sacubitril/valsartan", 
          "sacubitril/valsartan group", 
          "left ventricular ejection fraction", 
          "ventricular ejection fraction", 
          "HF hospitalization", 
          "control group", 
          "HFrEF patients", 
          "cause death", 
          "NYHA class", 
          "valsartan group", 
          "ejection fraction", 
          "conventional therapy", 
          "safety outcomes", 
          "reduced left ventricular ejection fraction", 
          "heart failure hospitalization", 
          "retrospective cohort study", 
          "comparable clinical features", 
          "significant side effects", 
          "symptomatic hypotension", 
          "renal function", 
          "cardiovascular mortality", 
          "cohort study", 
          "primary outcome", 
          "heart failure", 
          "clinical features", 
          "cardiac insufficiency", 
          "loop diuretics", 
          "receptor antagonist", 
          "observational study", 
          "side effects", 
          "hospitalization", 
          "patients", 
          "variable doses", 
          "hypotension", 
          "valsartan", 
          "efficacious molecules", 
          "angioedema", 
          "death", 
          "therapy", 
          "outcomes", 
          "months", 
          "group", 
          "ResultsMortality", 
          "enalapril", 
          "diuretics", 
          "hyperkalemia", 
          "strong protection", 
          "insufficiency", 
          "antagonist", 
          "mortality", 
          "doses", 
          "treatment", 
          "study", 
          "effect", 
          "failure", 
          "fraction", 
          "rate", 
          "protection", 
          "function", 
          "addition", 
          "features", 
          "HF", 
          "molecules", 
          "class", 
          "combination drug sacubitril/valsartan", 
          "drug sacubitril/valsartan", 
          "failure (HF) hospitalizations", 
          "MethodsOur retrospective cohort study", 
          "mineral receptor antagonist", 
          "ConclusionSacubitril/valsartan"
        ], 
        "name": "Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction", 
        "pagination": "425-432", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1100478773"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00059-017-4671-1"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "29350254"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00059-017-4671-1", 
          "https://app.dimensions.ai/details/publication/pub.1100478773"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:48", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_773.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00059-017-4671-1"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-017-4671-1'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-017-4671-1'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-017-4671-1'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-017-4671-1'


     

    This table displays all metadata directly associated to this object as RDF triples.

    224 TRIPLES      22 PREDICATES      112 URIs      100 LITERALS      19 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00059-017-4671-1 schema:about N24c09fc360c343acb056f3b7f6edc6b1
    2 N38dd5c9e3d2941ebbdc474aedf171de4
    3 N3d0b5e1f507d4996af2b4478eb4f0962
    4 N4b31632e95cd480aa0b32d77e4ae0cfe
    5 N594bde29dcf746859585a304f26a0edf
    6 N5f4f8a5e532e4bf7b632a80b6a464331
    7 N6cd8329d1b14492992fbc87fd0c4b984
    8 N9517a92965f44b118614d32e07989efd
    9 Nb826591a3c3a4d21b3700097adeb6b58
    10 Ncf3558eb08af42f5b79b3fb98e73553e
    11 Ne19eeedaa6b94dabb6a5b81719d14c7c
    12 Ne4fbdce669bf4f08a89138f7777d8f68
    13 anzsrc-for:11
    14 anzsrc-for:1102
    15 schema:author N6a06b58cd24049e394665041cc718c19
    16 schema:citation sg:pub.10.1007/164_2016_77
    17 sg:pub.10.1007/s00059-013-3772-8
    18 sg:pub.10.1007/s00059-017-4626-6
    19 sg:pub.10.1007/s11897-017-0327-y
    20 schema:datePublished 2018-01-19
    21 schema:datePublishedReg 2018-01-19
    22 schema:description BackgroundThe combination drug sacubitril/valsartan was reported to be superior to enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) hospitalizations in patients with cardiac insufficiency and reduced left ventricular ejection fraction (HFREF) with NYHA class II–IV.MethodsOur retrospective cohort study aimed to assess the effects of sacubitril/valsartan in addition to a beta-blocker and mineral receptor antagonist (MRA) in a group of HFREF patients with NYHA class II–III HF vs. conventional therapy (ACE inhibitor or angiotensin II receptor blocker added to a beta-blocker plus an MRA) administered to a control group of HFREF patients with comparable clinical features. In both groups, treatment was supplemented by a loop diuretic, usually furosemide, at variable doses. The primary outcomes were all-cause death and HF hospitalizations. Safety outcomes were symptomatic hypotension, angioedema, hyperkalemia, and worsening renal function.ResultsMortality at 6 months was 6.8% in patients taking sacubitril/valsartan vs. 34% in those on conventional therapy (odds ratio [OR] = 0.14; 95% CI: 0.04–0.49). Moreover, there was a 4.5% rate of HF hospitalizations in the sacubitril/valsartan group vs. 59% in the control group (OR = 0.03; 95% CI: 0.01–0.14). Safety outcomes were comparable in the two groups, although hypotension (systolic blood pressure < 100 mm Hg) was found in 15.9% of patients in the sacubitril/valsartan group vs. 5.7% in the control group (OR = 3.14; 95% CI: 0.94–10.55).ConclusionSacubitril/valsartan offered strong protection against all-cause death and HF hospitalizations at 6 months without any significant side effects. To validate this efficacious molecule, further postmarketing observational studies, focusing mainly on hypotension and angioedema are warranted.
    23 schema:genre article
    24 schema:inLanguage en
    25 schema:isAccessibleForFree false
    26 schema:isPartOf N024020c69e4d4234a01a2cf4a3ed1bfb
    27 Nfb6f008171f14902ba541ef9cfa8ef47
    28 sg:journal.1087175
    29 schema:keywords ConclusionSacubitril/valsartan
    30 HF
    31 HF hospitalization
    32 HFrEF patients
    33 MethodsOur retrospective cohort study
    34 NYHA class
    35 ResultsMortality
    36 addition
    37 angioedema
    38 antagonist
    39 cardiac insufficiency
    40 cardiovascular mortality
    41 cause death
    42 class
    43 clinical features
    44 cohort study
    45 combination drug sacubitril/valsartan
    46 comparable clinical features
    47 control group
    48 conventional therapy
    49 death
    50 diuretics
    51 doses
    52 drug sacubitril/valsartan
    53 effect
    54 efficacious molecules
    55 ejection fraction
    56 enalapril
    57 failure
    58 failure (HF) hospitalizations
    59 features
    60 fraction
    61 function
    62 group
    63 heart failure
    64 heart failure hospitalization
    65 hospitalization
    66 hyperkalemia
    67 hypotension
    68 insufficiency
    69 left ventricular ejection fraction
    70 loop diuretics
    71 mineral receptor antagonist
    72 molecules
    73 months
    74 mortality
    75 observational study
    76 outcomes
    77 patients
    78 primary outcome
    79 protection
    80 rate
    81 receptor antagonist
    82 reduced left ventricular ejection fraction
    83 renal function
    84 retrospective cohort study
    85 sacubitril/valsartan
    86 sacubitril/valsartan group
    87 safety outcomes
    88 side effects
    89 significant side effects
    90 strong protection
    91 study
    92 symptomatic hypotension
    93 therapy
    94 treatment
    95 valsartan
    96 valsartan group
    97 variable doses
    98 ventricular ejection fraction
    99 schema:name Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction
    100 schema:pagination 425-432
    101 schema:productId N088695c4bb534b5a9597856af4c0d37c
    102 N53c1c4afc2af4d54be03b98589a318b4
    103 N6dd5bea7bfc346cf92b8d487ad2e7ea7
    104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100478773
    105 https://doi.org/10.1007/s00059-017-4671-1
    106 schema:sdDatePublished 2022-01-01T18:48
    107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    108 schema:sdPublisher N156d5a21d8724980ac707cdfaae153aa
    109 schema:url https://doi.org/10.1007/s00059-017-4671-1
    110 sgo:license sg:explorer/license/
    111 sgo:sdDataset articles
    112 rdf:type schema:ScholarlyArticle
    113 N024020c69e4d4234a01a2cf4a3ed1bfb schema:volumeNumber 44
    114 rdf:type schema:PublicationVolume
    115 N088695c4bb534b5a9597856af4c0d37c schema:name dimensions_id
    116 schema:value pub.1100478773
    117 rdf:type schema:PropertyValue
    118 N156d5a21d8724980ac707cdfaae153aa schema:name Springer Nature - SN SciGraph project
    119 rdf:type schema:Organization
    120 N19cc6e694ab54b31af5e0f6f99c09eb2 rdf:first sg:person.01077606445.25
    121 rdf:rest rdf:nil
    122 N24c09fc360c343acb056f3b7f6edc6b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Retrospective Studies
    124 rdf:type schema:DefinedTerm
    125 N2955c1092a75451facf97c38834dc849 rdf:first sg:person.01066703417.19
    126 rdf:rest N19cc6e694ab54b31af5e0f6f99c09eb2
    127 N38dd5c9e3d2941ebbdc474aedf171de4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Neprilysin
    129 rdf:type schema:DefinedTerm
    130 N3d0b5e1f507d4996af2b4478eb4f0962 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Heart Failure
    132 rdf:type schema:DefinedTerm
    133 N4b31632e95cd480aa0b32d77e4ae0cfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Stroke Volume
    135 rdf:type schema:DefinedTerm
    136 N53c1c4afc2af4d54be03b98589a318b4 schema:name doi
    137 schema:value 10.1007/s00059-017-4671-1
    138 rdf:type schema:PropertyValue
    139 N594bde29dcf746859585a304f26a0edf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Humans
    141 rdf:type schema:DefinedTerm
    142 N5f4f8a5e532e4bf7b632a80b6a464331 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Tetrazoles
    144 rdf:type schema:DefinedTerm
    145 N6a06b58cd24049e394665041cc718c19 rdf:first sg:person.0704361014.79
    146 rdf:rest Ndc7e90b1275a412291d142dcf84685f6
    147 N6cd8329d1b14492992fbc87fd0c4b984 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Antihypertensive Agents
    149 rdf:type schema:DefinedTerm
    150 N6dd5bea7bfc346cf92b8d487ad2e7ea7 schema:name pubmed_id
    151 schema:value 29350254
    152 rdf:type schema:PropertyValue
    153 N9517a92965f44b118614d32e07989efd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Treatment Outcome
    155 rdf:type schema:DefinedTerm
    156 Nb826591a3c3a4d21b3700097adeb6b58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Male
    158 rdf:type schema:DefinedTerm
    159 Ncf3558eb08af42f5b79b3fb98e73553e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Aminobutyrates
    161 rdf:type schema:DefinedTerm
    162 Ndc7e90b1275a412291d142dcf84685f6 rdf:first sg:person.0660263343.51
    163 rdf:rest N2955c1092a75451facf97c38834dc849
    164 Ne19eeedaa6b94dabb6a5b81719d14c7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Drug Combinations
    166 rdf:type schema:DefinedTerm
    167 Ne4fbdce669bf4f08a89138f7777d8f68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Valsartan
    169 rdf:type schema:DefinedTerm
    170 Nfb6f008171f14902ba541ef9cfa8ef47 schema:issueNumber 5
    171 rdf:type schema:PublicationIssue
    172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    173 schema:name Medical and Health Sciences
    174 rdf:type schema:DefinedTerm
    175 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    176 schema:name Cardiorespiratory Medicine and Haematology
    177 rdf:type schema:DefinedTerm
    178 sg:journal.1087175 schema:issn 0340-9937
    179 1615-6692
    180 schema:name Herz
    181 schema:publisher Springer Nature
    182 rdf:type schema:Periodical
    183 sg:person.01066703417.19 schema:affiliation grid-institutes:None
    184 schema:familyName Di Biase
    185 schema:givenName G.
    186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066703417.19
    187 rdf:type schema:Person
    188 sg:person.01077606445.25 schema:affiliation grid-institutes:grid.9018.0
    189 schema:familyName Noutsias
    190 schema:givenName M.
    191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077606445.25
    192 rdf:type schema:Person
    193 sg:person.0660263343.51 schema:affiliation grid-institutes:None
    194 schema:familyName Ariano
    195 schema:givenName C.
    196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660263343.51
    197 rdf:type schema:Person
    198 sg:person.0704361014.79 schema:affiliation grid-institutes:None
    199 schema:familyName De Vecchis
    200 schema:givenName R.
    201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704361014.79
    202 rdf:type schema:Person
    203 sg:pub.10.1007/164_2016_77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000389269
    204 https://doi.org/10.1007/164_2016_77
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1007/s00059-013-3772-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047353802
    207 https://doi.org/10.1007/s00059-013-3772-8
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1007/s00059-017-4626-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091896405
    210 https://doi.org/10.1007/s00059-017-4626-6
    211 rdf:type schema:CreativeWork
    212 sg:pub.10.1007/s11897-017-0327-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1084033357
    213 https://doi.org/10.1007/s11897-017-0327-y
    214 rdf:type schema:CreativeWork
    215 grid-institutes:None schema:alternateName Division of Geriatrics, Casa di Cura “Sollievo della Sofferenza”, viale Cappuccini 2, 71013, San Giovanni Rotondo, Italy
    216 Division of Geriatrics, Clinic “S. Maria del Pozzo”, via Pomigliano 40, 80049, Somma Vesuviana, Italy
    217 Preventive Cardiology and Rehabilitation Unit, DSB 29 “S. Gennaro dei Poveri Hospital”, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy
    218 schema:name Division of Geriatrics, Casa di Cura “Sollievo della Sofferenza”, viale Cappuccini 2, 71013, San Giovanni Rotondo, Italy
    219 Division of Geriatrics, Clinic “S. Maria del Pozzo”, via Pomigliano 40, 80049, Somma Vesuviana, Italy
    220 Preventive Cardiology and Rehabilitation Unit, DSB 29 “S. Gennaro dei Poveri Hospital”, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy
    221 rdf:type schema:Organization
    222 grid-institutes:grid.9018.0 schema:alternateName Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst Grube-Straße 40, 06120, Halle, Germany
    223 schema:name Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst Grube-Straße 40, 06120, Halle, Germany
    224 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...